glp 1 drugs for inflammation GLP-1 calm beyond diabetes and weight loss GLP-1 Medications for Weight Loss:

J Natl Cancer Inst

doi: 10.1016/j.cmet.2006.10.001 [DOI] [PubMed] [Google Scholar] 26

The next generation of treatments GLP-1 receptor agonists have transformed the management of type 2 diabetes and obesity, but their therapeutic potential extends far beyond glucose regulation

Beyond Novo and Eli Lilly, companies such as Boehringer Ingelhium, Pfizer, Roche, AstraZeneca, Regor therapeutics, Viking Therapeutics, Amgen, BioAge Labs, Gan & Lee Pharmaceuticals, Sun Pharma, Innovent Biologics, Aphaia Pharma, Vertex Pharmaceuticals , and others are entering the space, fueling new innovations in GLP-1 therapies, combination therapies, and next-gen metabolic treatments

45,46 These results were confirmed by a pooled analysis that demonstrated that the improvement in quality of life and functional capacity may be primarily related to weight loss, and that there were significant declines in HF hospitalisations or urgent visits (8 [1%] versus 30 [5%] patients in the semaglutide and placebo groups, respectively

This study showed that the risk of recurrent pancreatitis in a cohort of patients taking GLP-1 receptor agonists (10%) was likely no greater than what is observed in the general population and that more than half of the episodes of recurrent pancreatitis were attributable to causes other than GLP-1 receptor agonist therapy